Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q4 FY24 results · Jan–Mar 2024
Gufic Biosciences reported revenue from operations of ₹194.99 crore and net profit of ₹20.05 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 194.99 | — | — | 201.78 | −3.4% |
| Other income | 0.88 | — | — | 0.42 | +108.1% |
| Total income | 195.87 | — | — | 202.20 | −3.1% |
| Profit before tax | 27.12 | — | — | 29.56 | −8.3% |
| Net profit for the period | 20.05 | — | — | 22.26 | −9.9% |
| EPS, basic (₹) | 2.00 | — | — | 2.23 | −10.3% |
| Net margin (%) | 10.3 | — | 11.0 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 194.99 | 173.04 | +12.7% | 201.78 | −3.4% |
| Other income | 0.88 | 0.62 | +41.4% | 0.42 | +108.1% |
| Total income | 195.87 | 173.66 | +12.8% | 202.20 | −3.1% |
| Profit before tax | 27.12 | 23.93 | +13.3% | 29.56 | −8.3% |
| Net profit for the period | 20.05 | 18.11 | +10.7% | 22.26 | −9.9% |
| EPS, basic (₹) | 2.00 | 1.87 | +7.0% | 2.23 | −10.3% |
| Net margin (%) | 10.3 | 10.5 | 11.0 |
Consolidated
- Filed with BSE
- 11 Jun 2024, 17:52 IST
- Board meeting
- 29 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Jun 2024, 17:52 IST
- Board meeting
- 29 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE